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Abstract
Dietary lycopene consists mostly of the (all-E) isomer. Upon absorption, (all-E) lycopene undergoes isomerisation into various (Z)-isomers.
Because these isomers offer potentially better health benefits than the (all-E) isomer, the aim of the present study was to investigate if the
profile of lycopene isomers in intestinal lipoproteins is affected by the profile of lycopene isomers in the meal and by the tomato prep-
aration. Six postprandial, crossover tests were performed in healthy men. Three meals provided about 70 % of the lycopene as (Z)-isomers,
either mainly as 5-(Z) or 13-(Z), or as a mixture of 9-(Z) and 13-(Z) lycopene, while three tomato preparations provided lycopene mainly as
the (all-E) isomer. Consumption of the 5-(Z) lycopene-rich meal led to a high (60 %) proportion of this isomer in TAG-rich lipoproteins
(TRL), indicating a good absorption and/or a low intestinal conversion of this isomer. By contrast, consumption of meals rich in 9-(Z)
and 13-(Z) lycopene isomers resulted in a low level of these isomers but high amounts of the 5-(Z) and (all-E) isomers in TRL. This indicates
that the 9-(Z) and 13-(Z) isomers were less absorbed orwere converted into 5-(Z) and (all-E) isomers. Dietary (Z)-lycopene isomers were, there-
fore, differently isomerised and released in TRL during their intestinal absorption in men. Consuming the three meals rich in (all-E) lycopene
resulted in similar proportions of lycopene isomers in TRL: 60 % (all-E), 20 % 5-(Z), 9 % 13-(Z), 2 % 9-(Z) and 9 % unidentified (Z)-isomers. These
results show that the tomato preparation has no impact on the lycopene isomerisation occurring during absorption in humans.
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Lycopene is an acyclic C40 non-polar carotenoid, present in
several dietary sources such as tomato, watermelon, guava
and apricot. Although not being a provitamin A, lycopene
has been shown to have multiple biological activities
including decreasing the risk of prostate cancer(1), inhibition
of cell proliferation, migration and invasion in breast of
endometrial and liver carcinoma cells(2–7), and prevention of
mutagenesis and chromosome instability(8,9). In addition, a
variety of epidemiological trials indicated that high intakes
of lycopene-containing foods (primarily tomato products) or
elevated blood lycopene concentrations are associated with
a decreased risk of CVD and prostate cancer(10–13).
Lycopene has eleven conjugated double bonds and each of
them could be either in an (E) or (Z) configuration. (All-E)
lycopene is the predominant isomer in plants, representing
about 80–97 % of total lycopene in tomatoes and related
products(14). In human body fluids and tissues such as
plasma, prostate, testis and skin, 25–70 % of lycopene is
found in various (Z) forms(15–20). The high concentrations of
(Z)-isomers in vivo trigger the hypothesis that they are more
bioavailable and/or that (all-E) lycopene is transformed into
(Z)-isomers within the human body. Moreover, when a
tomato-based meal rich in the (all-E) isomer is consumed daily
over a few weeks, plasma lycopene concentration increases
and its main part (60%) is present as (Z)-isomers(21). Recently,
we have demonstrated that lycopene isomerisation takes place
in the enterocytes and not in the gastrointestinal lumen(22).
In terms of bioactivity, Shi & Le Maguer(14) indicated that the
biological potency of (Z)-lycopene isomers is different from
that of the (all-E) form. Bo¨hm et al.(23) reported that some
(Z)-isomers have a stronger in vitro antioxidant activity than
the (all-E) form. For these reasons, (Z)-lycopene isomers are
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regarded as offering potentially better health benefits than the
(all-E)-isomer.
In the present study, we investigated, in human subjects,
the effect of meals enriched in lycopene on the lycopene
isomer profile of plasma TAG-rich lipoprotein (TRL) frac-
tions. The main objective was to compare the profile of
lycopene isomers appearing in TRL following the ingestion
of tomato preparations rich in (Z)-lycopene isomers. Three
different tomato preparations rich in Z-lycopene (about
70 % of total lycopene) were produced. One preparation
was rich in 5-(Z) (65 %), one in 13-(Z) (42 %) and one in
a mixture of 9-(Z) (31 %) and 13-(Z) (24 %) isomers. Another
objective was to determine if the tomato preparation can




Tomato preparations rich in (Z)-lycopene isomers
Tomato preparation rich in 5-(Z) lycopene isomer. Produced
by mixing 10 g of tomato oleoresin in 500 ml dichloro-
methane with 580ml iodine solution (5·6 mg iodine in
596ml methylene chloride). The mixture was photoi-
somerised for 10 h at room temperature. Photoisomerised
tomato oleoresin was further enriched in 5-(Z) lycopene by
successive fractionation in ethanol and in ethyl acetate. The
solid fraction was then re-suspended in ethyl acetate (1:80
w/w) and the suspension centrifuged at 16 900 g for 5 min
at room temperature. The solid fraction was discarded and
the tomato preparation enriched in 5-(Z) lycopene was
obtained by distilling ethyl acetate under reduced pressure
at 308C. This preparation provided 65 % of total lycopene
as 5-(Z) isomer (Table 1).
Tomato preparation rich in 13-(Z) lycopene isomer. A sus-
pension of tomato oleoresin in ethyl acetate (1:10 v/v) was
refluxed for 1 h under stirring. After cooling to room tempera-
ture, the precipitate (approximately 10 % w/w of initial raw
material) was filtered off. This precipitate contained mainly
(all-E) lycopene isomer. The isomerised tomato preparation
was obtained by evaporating ethyl acetate from the filtrate
under reduced pressure at 308C and by azeotropic distillation
after addition of water and ethanol (water:ethanol ratio: 8:2).
This preparation provided 70 % of total lycopene as
(Z)-isomers with 42 % as 13-(Z) lycopene (Table 1).
Tomato preparation rich in 9- and 13-(Z) lycopene isomers.
A similar process as the one described for the tomato
preparation rich in 13-(Z) lycopene was performed, with the
exception that the heating duration had been increased up
to 24 h. This preparation provided 72 % of total lycopene as
(Z)-isomers, with 31 % as 9-(Z) lycopene and 24 % as 13-(Z)
lycopene (Table 1).
Tomato preparations rich in (all-E) lycopene. Three
tomato products, i.e. a commercial tomato paste packed in a
300 g tube (Thomy, Vevey, Switzerland), a tomato oleoresin
(Indena, Milan, Italy) and a Lactolycopenee preparation
(Indena), contained about 95 % of total lycopene as the
(all-E) isomer.
The lycopene isomer profiles of the tomato supplements are
presented in Fig. 1 and Table 1. With the exception of tomato
paste, the daily doses of test products were packed separately
as aliquots in light-protected containers, sealed under N2 and
stored at 2808C during the course of the study. The lycopene
content and profile of isomers were shown to be stable for 6
months at 2408C in the tomato products, indicating that the
storage conditions were adequate.
Subjects
A total of thirty healthy men were enrolled in the study. Of
these, twenty-seven subjects, aged 24 (SEM 1) years, completed
the study. Their mean starting body weight was 70 (SEM 1) kg
and BMI 22·5 (SEM 0·3) kg/m2. Subjects were normolipidaemic,
i.e. they had a ratio of plasma cholesterol to HDL cholesterol
,5·0 and plasma TAG concentrations ,1·5 mmol/l. Because
of the large amount of blood that was drawn during the
study, subjects were required to have a blood Hb concen-
tration .1·3 g/l as inclusion criteria. The subjects did not use
medication; neither did they have a history of gastrointestinal
disease or lipid metabolic disorders. Three volunteers
abandoned the trial before the end for the following reasons:
unavailability, medical treatment related to an eye injury,
nausea related to the consumption of fatty meals.
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and all
procedures involving human subjects were approved by the
ethical committee of Marseille (Marseille, France). All subjects
received information on background and design of the study
and gave written informed consent before participation.
They were free to withdraw from the study at any time.
Study design
The study was a randomised, six-period, six-treatment cross-
over clinical trial with a washout period of 3 weeks minimum.
Subjects and technicians were blinded while the investigator
was blinded for five tomato products but not for the tomato
paste which was a commercial product. Subjects were asked
to refrain for 48 h before the postprandial tests from eating
lycopene-rich products: tomatoes (crude, cooked and
tomato sauces including ketchup and harissa), pizza, rata-
touille, lasagna, pasta including tomato sauce, watermelon,
pink grapefruits and guava. In addition to this dietary
Table 1. Lycopene isomer profile of the six lycopene preparations
(Percentage of the total lycopene)
Lycopene preparation x-(Z) 5-(Z) 9-(Z) 13-(Z) (All-E)
Tomato paste ND 4·1 ND 0·1 95·8
Tomato oleoresin ND 4·1 ND 0·1 95·8
Lactolycopene ND 4·1 ND 0·1 95·8
Tomato preparation rich
5-(Z) lycopene ND 65·3 1·3 ND 33·4
13-(Z) lycopene 12·0 7·6 9·6 41·5 29·3
9- and 13-(Z) lycopene 10·2 7·7 30·8 23·5 27·8
ND, not defined.
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restriction, the subjects ate a standard meal the evening
before the postprandial tests consisting of green vegetables,
a source of cereals (pasta, bread or rice), lean meat or fish,
low-fat natural yoghurt, one fruit and mineral water. They
had to consume this dinner in the evening between 19.00
and 20.00 hours. These recommendations were checked by
the investigator on the postprandial test day.
After an overnight fast, subjects arrived at the Clinical
Pharmacology and Therapeutic Trial Center of the University
of Marseille (Marseille, France) and consumed a standard meal
consisting of semolina (70 g) cooked in 200 ml hot water,
white bread (40 g), egg-whites (60 g), groundnut oil (40 g),
natural yoghurt (125 g), sugar (5 g) and water (330 g). This
standard meal provided 842 kcal (3520 kJ) with the following
nutrient composition: protein (11·7 %), carbohydrates
(39·3 %) and lipids (49·0 %). A portion of one of the six lyco-
pene preparations adapted to provide 25 mg of lycopene
was incorporated into the test meal just before its consump-
tion. This meal was consumed within 30 min. No other
food was allowed over the following 6 h, but the subjects
were allowed to drink bottled water up to a maximum of
330 ml. Fasting blood was drawn from an anticubital vein by
venepuncture into an evacuated tube containing potassium
EDTA/K3 that was immediately placed in an ice-water-bath
and covered with an aluminium foil to avoid light exposure.
Blood samples were collected 20 min and 5 min before con-
sumption of the standard meal as well as after 2, 3, 4, 5 and
6 h post-absorption.
This short postprandial time frame, i.e. 6 h, was chosen to
assess lycopene isomerisation within the intestine with as
low contamination by lycopene isomers coming from other
organs (mainly the liver) as possible. Indeed, during the post-
prandial period, chylomicrons secreted by the intestine, which
contained lycopene coming from the meal, are transformed
into chylomicron remnants following TAG hydrolysis by lipo-
protein lipase. These chylomicron remnants are taken up by
the liver. A fraction of dietary lycopene is then incorporated
in VLDL and released in the blood. It is not known, but poss-
ible, that an isomerisation of lycopene also occurs in the liver
leading to an increase in blood concentration of lycopene iso-
mers. Because liver VLDL start to be produced some hours
after a fat meal intake, the longer the postprandial period,
the higher the level in the blood of VLDL coming from the
liver. As, technically, it is quite complicated to isolate the
chylomicron remnants from the VLDL, we decided to collect
the TRL during the initial postprandial period so that they
contain mostly lipoproteins of intestinal origin.
Blood sample preparation
Tubes containing the blood were protected from light, stored
at 48C and then centrifuged within 2 h (10 min, 48C, 878 g) to
separate the plasma. On the test day, plasma (6 ml) was
overlaid with 0·9 % NaCl solution and centrifuged for 28 min
at 130 000g at 108C in an SW41Ti rotor (Beckman, Fullerton,
CA, USA) in an L7 ultracentrifuge (Beckman). The upper
phase containing TRL, i.e. mainly chylomicrons and chylo-
micron remnants, was collected. Immediately after recovery,
TRL were divided into aliquots and immediately stored at
2808C before lycopene isomer profile determination.
Analytical procedures
The profile of lycopene isomers was determined according
to the method described previously by Schierle et al.(18) for
lycopene products (Fig. 1), and according to the method of
Ferruzzi et al.(24) for TRL. The main lycopene isomers
identified were 5-(Z), 9-(Z), 13-(Z) and (all-E) lycopene.
Minor compounds eluting between 24 and 48 min (Fig. 1)
were identified as (Z)-lycopene by LC–MS/MS using an
Applied Biosystems APCI 4000 LC–MS/MS (Foster City, CA,
USA). The following conditions were used: isocratic flow,
1 ml/min; declustering potential, 130 V; 60 pounds per square
inch (414 kPa) N2; capillary voltage, 22 V; vaporiser temp-
erature, 4008C; corona needle, 5 mA; the fragmentation
conditions used were those described by dos Anjos Ferreira
et al.(25). The peak areas of unidentified (Z)-lycopene isomers
were summed up and reported as x-(Z) lycopene (Table 1).
Retention time (min)
20 300 10 40 50
Tomato paste
Preparation rich in 9-
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Fig. 1. HPLC chromatograms of the lycopene isomer profiles in the
tomato paste rich in (all-E) lycopene and in the three tomato preparations
rich in (Z)-lycopene isomers.
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Data analyses
The raw data consisted of TRL-lycopene isomer concentrations
(expressed in mmol/l) of five lycopene isomers, i.e. x-(Z),
5-(Z), 9-(Z), 13-(Z) and (all-E), measured at six time points
(before and, 2, 3, 4, 5 and 6 h after ingestion of the standar-
dised meal containing lycopene) for each of the six different
test meals and each of the twenty-seven subjects. These raw
data were averaged for the twenty-seven subjects and pre-
sented as means with their standard errors for each time
point (Fig. 2). The baseline was the average of the two lyco-
pene concentrations measured in plasma samples collected
before consumption of the meal. As our goal was to determine
lycopene isomerisation during the absorption phase, we
voluntarily limited the measurement of lycopene isomer
profiles to a short period of time after lycopene intake.
Thus, we measured mainly lycopene present in chylomicrons
in the TRL fraction, with only some lycopene present in the
VLDL fraction coming from the liver. These purely descriptive
analyses confirmed that lycopene concentrations did not
return to baseline 6 h after ingestion of the test meal. In
consequence, no formal kinetics modelling (e.g. area under
the curve, Tmax or Cmax) was further considered. In order to
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Fig. 2. TAG-rich lipoproteins-lycopene isomer concentrations over 6 h post-consumption of the standard meals providing 25 mg lycopene from various sources.
(a) Preparation rich in 5-(Z) lycopene, (b) preparation rich in 13-(Z) lycopene, (c) preparation rich in 9-(Z) and 13-(Z) lycopene, (d) tomato paste rich in (all-E) lycopene,
(e) lactolycopene rich in (all-E) lycopene and (f) oleoresin rich in (all-E) lycopene. Values are means, with their standard errors represented by vertical bars (nmol/l,
n 27). x-(Z) lycopene (V); 5-(Z) lycopene (B); 9-(Z) lycopene (O);13-(Z) lycopene ( £ ); (all-E) lycopene (*).
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discussion of results, individual lycopene isomers were
expressed as relative percentage of the total lycopene calcu-
lated as the sum of the five lycopene isomers, i.e. x-(Z), 5-
(Z), 9-(Z), 13-(Z) and (all-E) (Fig. 3).
Results
Following the ingestion of the six standardised meals sup-
plemented with lycopene, TRL-lycopene concentrations
increased promptly, reaching a first maximum concentration
between 2 and 4 h, and started to increase again after 5 h
(Fig. 2). Since lycopene isomer profiles were determined
over a short period of time only, the second maximum was
not well characterised. These two rises of lycopene concen-
trations are in agreement with the known lycopene absorption
processes and show a first appearance of dietary lycopene in
chylomicrons (before 4 h) and a subsequent incorporation of
dietary lycopene chylomicrons into newly released VLDL
from the liver (after 5 h). In consequence, our choice for a
short postprandial time frame (0–6 h), which accounts for
the appearance of lycopene in chylomicrons, is ideal to deter-
mine lycopene isomerisation within the intestine.
Interestingly, the profile of lycopene isomers expressed in
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Fig. 3. TAG-rich lipoproteins-lycopene isomer profiles over 6 h post-consumption of the standard meals providing 25 mg lycopene from various sources. (a) Prep-
aration rich in 5-(Z) lycopene, (b) preparation rich in 13-(Z) lycopene, (c) preparation rich in 9-(Z) and 13-(Z) lycopene, (d) tomato paste rich in (all-E) lycopene, (e)
lactolycopene rich in (all-E) lycopene and (f) oleoresin rich in (all-E) lycopene. Values are means, with their standard errors expressed as percentage of the total
lycopene represented by vertical bars (n 27). x-(Z) lycopene (V); 5-(Z) lycopene (B); 9-(Z) lycopene (O); 13-(Z) lycopene ( £ ); (all-E) lycopene (*).
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Moreover, the inter-individual variability of concentrations
(Fig. 2) and percentages of lycopene (Fig. 3) were very small.
Proportion of lycopene isomers in TAG-rich
lipoprotein after consumption of tomato preparations
rich in (Z)-lycopene
Consumption of a tomato preparation rich (65 %) in 5-(Z)
lycopene resulted in a close proportion (60 %) of this isomer
in TRL, suggesting a good absorption and a low isomerisation
of this isomer in the enterocytes (Figs. 2(a) and 3(a)). The
other lycopene isomers observed in TRL consisted of 20 % of
(all-E), 9 % of x-(Z), 7 % of 13-(Z) and 2 % of 9-(Z). Since
these (Z)-isomers were not present in the diet, their appear-
ance in TRL suggests that they were formed during absorption
by isomerisation of the (all-E) lycopene.
Only a low amount (9 %) of the 13-(Z) isomer was measured
in TRL following the intake of a tomato preparation which
contained 42 % of this isomer (Figs. 2(b) and 3(b)). Other lyco-
pene isomers measured in TRL were mainly the (all-E) (about
50 %) and the 5-(Z) (25 %) isomers, suggesting that part of the
13-(Z) lycopene was isomerised into these isomers during
absorption.
Eating the tomato preparation rich in a mixture of 9-(Z) and
13-(Z) lycopene induced a release of lycopene in TRL contain-
ing mostly the (all-E) (42 %) and 5-(Z) (27 %) isomers (Figs.
2(c) and 3(c)), suggesting that the 9-(Z) and 13-(Z) isomers
were isomerised into the (all-E) and 5-(Z) isomers.
Proportion of lycopene isomers in TAG-rich lipoprotein
after consumption of tomato preparations rich in (all-E)
lycopene
Consumption of the tomato paste rich in (all-E) lycopene
(about 95 %) resulted in observing various lycopene isomers
in TRL, i.e. roughly 60 % (all-E) and 40 % (Z)-isomers, with
about 18 % of 5-(Z), 10 % of 13-(Z) and x-(Z), and 2 % of
9-(Z) (Figs. 2(d) and 3(d)). The appearance of isomers that
were not detected in the tomato paste, i.e. 9-(Z), 13-(Z) and
x-(Z), strongly suggests that part of the (all-E) was isomerised
during absorption.
The same profile of lycopene isomers in TRL was also
observed with the two other tomato preparations, i.e. lactoly-
copene and oleoresin, containing about 95 % (all-E) lycopene
(Figs. 2(e), (f) and 3(e), (f)). These results indicate that the
three tomato preparations rich in the (all-E) isomer were simi-
larly isomerised during their absorption in human subjects
and, therefore, that the lycopene foodmatrix didnot influence it.
Discussion
We have recently demonstrated that, during absorption, a sig-
nificant isomerisation of (all-E) lycopene into various (Z)-lyco-
pene isomers takes place in human enterocytes(22). The
first objective of the present study was to determine if the
lycopene isomer profile in the blood circulation was affected
by the isomer profile in the meal.
Consumption of the tomato preparation rich in 5-(Z) lyco-
pene led to a very high proportion of 5-(Z) lycopene isomer
in TRL (about 60 %), which indicates either a good absorption,
or a greater thermodynamical stability(26) of this isomer,
or both.
The consumption of either a preparation rich in a mixture of
9-(Z) and 13-(Z) or a preparation rich in 13-(Z) lycopene was
associated with the release of TRL which contained lower pro-
portions of these two isomers as compared to those present in
the tomato preparations. These results indicate either a low
absorption of these isomers or an isomerisation of these iso-
mers into more thermodynamically stable lycopene isomers,
i.e. (all-E) and 5-(Z), during absorption. The second hypoth-
esis seems the most likely, as the proportion of the (all-E)
and 5-(Z) isomers measured in TRL after intake of the prep-
aration rich in 9-(Z) and 13-(Z) isomers was higher than in
the preparation itself.
These results show that although the human intestine is able
to modify the profile of dietary lycopene isomers which is
finally found in the body, the resulting profile is not the
same for all isomer sources supplied but is dependent on
the initial relative proportions of these isomers existing in
the meal. This suggests that the mechanism of (E)-to-(Z)
conversion can be overwhelmed by offering high amounts
of dietary lycopene (Z)-isomers, e.g. 5-(Z). It is, therefore,
possible to modulate the profile of (Z)-isomers which enter
the human body via the intestinal lipoproteins by a lycopene
isomer-rich diet.
Besides, it is well known that the bioavailability of (all-E)
lycopene is dependent on the tomato preparation(21). In
agreement with results reported in the literature(15,17,27), we
have shown that consuming a tomato paste which contained
mainly (95 %) (all-E) lycopene resulted in secretion of TRL
containing 40 % of lycopene (Z)-isomers(21,22), which suggests
that part of the ingested (all-E) lycopene was converted into
(Z)-isomers. The secondary objective of this work was to
assess whether the preparation of (all-E) lycopene affects the
isomerisation of the (all-E) lycopene during intestinal absorp-
tion. Present results show that consumption of the three
tomato preparations rich in the (all-E) isomer (tomato paste,
(all-E) oleoresin and lactolycopene) resulted in a similar iso-
merisation of the (all-E) lycopene. This shows that lycopene
isomerisation occurring in the enterocytes is not significantly
affected by the lycopene preparation. Another key obser-
vation is that the main (Z)-isomer recovered in TRL was the
5-(Z) lycopene (about 20 % of the total lycopene content).
This suggests that either the 5-(Z) lycopene is specifically
formed during isomerisation of the (all-E) lycopene, or the
5-(Z) isomer, being more stable than the others(26), leads to
its preferential accumulation during absorption, or both.
Interestingly, there is a low inter-individual variation of
lycopene isomerisation during intestinal absorption, which is
in agreement with previous results observed with tomato
paste(22).
(Z)-lycopene isomers have been discussed for their specific
bioactivity. Indeed, individual (Z)-lycopene isomers exhibit
different antioxidant activities(23) and some human organs
like prostate(16) and skin accumulate high amounts of
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(Z)-lycopene isomers. More research is needed to evaluate
how chronic supplementation with a diet enriched in (Z)-lyco-
pene isomers will affect their distribution in tissues and sub-
sequently will modulate lycopene bioactivity in humans.
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